GSK3B and neoplasm: These trials are rationally supported by the differential roles of GSK3β in cellular signaling events between normal and tumor cells and by the phosphorylation-dependent regulation of GSK3β activity that presumably protects normal cells from transformation by GSK3β inhibition [9]–[12], [14].